Tags |
|
|
Links |
|
|
Digg It - Medical Billing - GP0 Record Fields 22 Through 33
We're finally coming to the end of our review of the GP0 record for medical billing of claims via electronic media, using NSF 3.01 specifications. In this inst
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
allment we'll be covering the last twelve fields, which is where most of the differences are between the parental nutrition CMN and the enteral nutrition CMN, w
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
hich we reviewed previously when we covered the GE0 record. We pick up this installment with field number 22.
GP0 field 22, positions 78 - 92, is the amino ac
GP0 field 22, positions 78 - 92, is the amino ac
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
id name. This is the field that tells the carrier the name of the amino acid that is being administered to the patient. This field must be filled in with the
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
ctual name of the acid. No abbreviations or brand names allowed.
GP0 field 23, positions 93 - 96, is the amino acid volume. This field tells the carrier how
GP0 field 23, positions 93 - 96, is the amino acid volume. This field tells the carrier how
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
much of the amino acid the patient is to receive per day, not per feeding, for parental nutrition therapy. This amount is transmitted in milliliters and must b
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
e exact.
GP0 field 24, positions 97 - 101, is the amino acid concentration. This field tells the carrier what the exact percentage of concentration is for the
GP0 field 24, positions 97 - 101, is the amino acid concentration. This field tells the carrier what the exact percentage of concentration is for the
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
amino acid that is being given to the patient for parental nutrition therapy. In this case, a decimal is used to show a concentration that is less than a whole
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
percentage, like 10.5%.
GP0 field 25, positions 102 - 105, is the amino acid weight. This field tells the carrier how much the amino acid that is given per d
GP0 field 25, positions 102 - 105, is the amino acid weight. This field tells the carrier how much the amino acid that is given per d
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ay, weighs in grams. If the number of grams prescribed per day is greater than 100, then a narrative explanation must be given in field number 31.
GP0 field 2
GP0 field 2
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
, positions 106 - 109, is the dextrose volume. This field tells the carrier how much dextrose is in the prescription given to the patient, per day. This field
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
is transmitted in milliliters and must be exact.
GP0 field 27, positions 110 - 114, is the dextrose concentration. This field tells the carrier what the perc
GP0 field 27, positions 110 - 114, is the dextrose concentration. This field tells the carrier what the perc
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
entage of dextrose is, in relation to the entire solution given to the patient on a daily basis. As with field number 24, a decimal is used if not a whole perc
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
entage.
GP0 field 28, positions 115 - 118, is the lipids volume. This field tells the carrier what the volume of lipids is given to the patient on a daily bas
GP0 field 28, positions 115 - 118, is the lipids volume. This field tells the carrier what the volume of lipids is given to the patient on a daily bas
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
s. This field is also transmitted in milliliters and must be exact.
GP0 field 29, positions 119 - 123, is the lipids concentration. This field tells the carr
GP0 field 29, positions 119 - 123, is the lipids concentration. This field tells the carr
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
ier what the percentage of lipids is in relation to the whole mixture, given to the patient on a daily basis.
GP0 field 30, positions 124 - 126, is the lipids
GP0 field 30, positions 124 - 126, is the lipids
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
frequency. This tells the carrier how many times per week lipids are used in therapy.
GP0 field 31, positions 127 - 226, is the narrative field. This field i
GP0 field 31, positions 127 - 226, is the narrative field. This field i
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
used to give the carrier any information that is not covered above that is required, such as explanations.
GP0 field 32, position 227, is the administration t
GP0 field 32, position 227, is the administration t
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
echnique indicator. This field is used to tell the carrier how the parental nutrition is being administered. Valid entries are N, G, J, or O.
GP0 field 33, p
GP0 field 33, p
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
ositions 228 - 320, is filler national and must be filled with spaces.
In our next installment of medical billing, we'll cover another in the long list of CMNs
In our next installment of medical billing, we'll cover another in the long list of CMNs
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/2268/diggit-Medical-Billing--GP0-Record-Fields-22-Through-33.html">Medical Billing - GP0 Record Fields 22 Through 33</a>
BB link (for phorums):
[url=http://www.diggit.org.ua/article/2268/diggit-Medical-Billing--GP0-Record-Fields-22-Through-33.html]Medical Billing - GP0 Record Fields 22 Through 33[/url]
Related Articles:
Dealing With Office Distractions, Part Two - Unnecessary Work
3 Ways To Profit From The NFL During The Off Season
How To Incorporate In Connecticut
Bookmark it:
|